JNJ Stock Recent News
JNJ LATEST HEADLINES
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids SPRING HOUSE, Pa. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sus
The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.
Trump tariffs have already hurt US stocks significantly in recent weeks but the Fed's latest warning of stickier inflation and an economic slowdown ahead signals the worst may not be over just yet.
Those who own JNJ stock may stay invested for some time, as the company is optimistic about a better performance in 2025.
JNJ announces plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the United States.
I have added Canadian Natural Resources and NextEra Energy to The Dividend Income Accelerator Portfolio, each representing 2.19% of our overall portfolio. These strategic acquisitions help us to further optimize the portfolio's mix of dividend income and dividend growth. After these acquisitions, our dividend portfolio offers investors a Weighted Average Yield on Cost [TTM] of 4.43% and a 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.53%.
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.